-
The dual-channel target CDK7 R&D track is worthy of follow-up!
Time of Update: 2021-10-20
2 The mechanism steps of CDK7 showing more physiological functions (see references for pictures) 03 Varieties entering the clinical stage worldwide According to reports, THZ1 is the first reported synthetic CDK7-specific covalent small molecule inhibitor in 2014, and it is also CDK12/ 13 Inhibitors: In vivo and in vitro, it can inhibit the proliferation of tumor cells of different genotypes and phenotypes.
-
The mission of gene therapy: the long march from rare disease drugs to mainstream drugs
Time of Update: 2021-10-20
To provide a free and unobstructed communication platform for innovative drug practitioners, Sina Pharmaceuticals specially launched the "Xinzhihui" online live knowledge sharing platform, which will focus on target discovery in drug research and development, new technology development and application, process development and verification, and drug clinical practice.
-
? Patent analysis of small molecule drug design (WuXi AppTec ddsu article)
Time of Update: 2021-10-11
Exposure (7739 vs 2316 nM*h) and better oral availability (52% vs 22%); compound 49 is superior to ARS-1620 in the human non-small cell lung cancer NCI-H358 subcutaneous allograft tumor model In vivo drug effect, and the anti-tumor effect has a dose-dependent trend .
-
Kinetisol? technology broadens the preparation space and analyzes its application in the preparation of pharmaceutical amorphous solid dispersions
Time of Update: 2021-10-11
The exposure time of the material under high temperature is usually less than 5 seconds, such as When Kinetisol is used to prepare amorphous solid dispersions of itraconazole, the heating time and amount of heat are significantly lower than that of hot melt extrusion technology, as shown in Figure 3.
-
Innovent announced the preliminary results of the Phase Ia dose escalation study of IBI315 (anti-Her2/PD-1 bispecific antibody) in patients with advanced solid tumors at the CSCO annual meeting in 2021
Time of Update: 2021-10-10
Professor Xichun Hu from the Cancer Hospital of Fudan University said: "IBI315 has shown good safety and preliminary effectiveness in the phase Ia study, and preliminary verification of the bispecific antibody design combining targeted therapy and immunotherapy .
-
Medical companies join hands to carry out chip-level source innovation research
Time of Update: 2021-10-10
Zhao Guoguang, Dean of Xuanwu Hospital, expressed the hope that through the all-round strategic cooperation between the two parties, a new benchmark for the integration and innovation of industry, university, research and medical will be established, and forward-looking explorations will be carried out on the precise diagnosis and treatment of neurological diseases and brain science, and jointly build the vanguard of the National Medical Center and build a healthy China.
-
Who can change the pattern of atopic dermatitis treatment?
Time of Update: 2021-10-10
Two key phase III trials of Lebrikizumab, another IL-13 targeting antibody, ADvocate1 and ADvocate2, also reported reaching the 16-week EASI-75 primary endpoint.
-
Aceclofenac of non-steroidal anti-inflammatory drugs (NSAIDs)
Time of Update: 2021-10-10
2) Rheumatoid Arthritis On February 6, 2005, the drug was approved by the National Medical Products Administration of China NMPA and sold by Guangzhou Baiyunshan Guanghua Pharmaceutical Co.
Aceclofenac, as a non-steroidal anti-inflammatory drug (NSAID), has been approved to relieve pain and inflammation of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis .
-
Is the target CDK2 the highest stage clinical phase III worthy of further follow-up?
Time of Update: 2021-10-10
Among them, the targeted regulation of tumor cell cycle to change the apoptotic state of tumor cells has been clinically proven to be effective, and the specific representative species is the CDK family inhibitor .
-
How to write a clinical risk management plan for CAR-T cell therapy products that meets the registration requirements
Time of Update: 2021-10-10
On September 18, 2021, the official website of the Center for Drug Evaluation of the National Medical Products Administration issued the "Chimeric Antigen Receptor T Cell (CAR-T) Product Application and Marketing Clinical Risk Management Plan Technical Guidelines (Draft for Solicitation of Comments)" for comments The time limit is 1 month from the date of issuance.
-
World Alzheimer's Day: How to improve the safety, compliance and accessibility of medicines?
Time of Update: 2021-10-01
How to improve the treatment effect of Alzheimer's disease, reduce the side effects of drugs, improve patient compliance, reduce the burden of family care, and increase the accessibility of drugs are problems that the medical community faces urgently to be resolved .
-
How does "machine learning" help new drug development?
Time of Update: 2021-10-01
Machine learning (ML), as a branch of artificial intelligence, has multiple methods used in the drug discovery process to predict the molecular characteristics, biological activities, interactions, and adverse reactions of new chemical entities .
-
Progress in clinical trials of drug treatment for dry eye in the past three years
Time of Update: 2021-09-30
Recently, Cornea magazine published the positive results of a phase 2b/3 clinical trial of CyclASol 0. 1%, a non-water drop eye solution of CyclASol, which was completed by Novaliq GmbH of Germany, f
-
Idiopathic pulmonary fibrosis (IPF) of rare diseases in China
Time of Update: 2021-09-30
1. Transforming growth factor β1 (TGF-β1) TGF-β family members include TGF-β1, TGF-β2 and TGF-β3, which are involved in inflammation, wound healing, extracellular matrix accumulation, bone formation, tissue development, cell differentiation and tumors progress and so on .
-
Sales of mythical new oral anticoagulant drugs
Time of Update: 2021-09-29
Therefore, compared with warfarin, the efficacy of dabigatran etexilate is predictable, and there is no need for regular blood coagulation monitoring during clinical use, and the drug is not metabolized by the liver CYP enzyme, and the drug is taken with proton pump inhibitors and H2 receptor antagonists.
-
CSCO2021 Professor Li Jin: New hope for HER2-positive solid tumors, Phase I study of new ADC drug MRG002 announced
Time of Update: 2021-09-29
On September 25-29, 2021, the 24th National Conference on Clinical Oncology and the 2021 CSCO Academic Annual Meeting will be held as scheduled to promote the continuous development of China's oncolo
-
Merck's $300 million anti-infective drug meets its rivals again!
Time of Update: 2021-09-20
Data source: CDE official website, Minet database A few days ago, the official website of CDE showed that Qilu Pharmaceutical (Hainan) was accepted for posaconazole injection with imitation of 4 types of applications .
-
Shake shop rights increase, 30 days of green planting and death compensation rights to help merchants reduce costs and increase efficiency
Time of Update: 2021-09-19
" Fulfilling the dead " helps merchants reduce costs and increase efficiency Shaodian’s “ Green Plants Nourishment Insurance ” is a way to improve consumer rights, so that merchants have three major operating advantages: exclusive logos, traffic weighting, and cost reduction and efficiency enhancement .
-
Talking about the BRD4 inhibitors under clinical research, some are advancing, some are struggling
Time of Update: 2021-09-18
However, with the successive failures of small molecule inhibitors of different structures developed by major companies in clinical tumor indications, whether BRD4 is a target that can be made into drugs has also been aroused a lot of discussion.
-
Looking at PD-(L)1×TGF-β from ESMO in 2021
Time of Update: 2021-09-18
Figure: M7824 mechanism of action Data source: Merck (2) SHR-1701 is an anti-PD-L1×TGF-βRⅡ bifunctional fusion protein independently developed by Hengrui Medicine, which can block the PD-1/PD-L1 pathway and neutralize TGF- in the tumor microenvironment.
